Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4)

The epigenetic silencing of exogenous transcriptional units integrated into the genome represents a critical problem both for long-term gene therapy efficacy and for the eradication of latent viral infections. We report here that limitation of essential amino acids, such as methionine and cysteine, causes selective up-regulation of exogenous transgene expression in mammalian cells. Prolonged amino acid deprivation led to significant and reversible increase in the expression levels of stably integrated transgenes transcribed by means of viral or human promoters in HeLa cells. This phenomenon was mediated by epigenetic chromatin modifications, because histone deacetylase (HDAC) inhibitors reproduced starvation-induced transgene up-regulation, and transcriptome analysis, ChIP, and pharmacological and RNAi approaches revealed that a specific class II HDAC, namely HDAC4, plays a critical role in maintaining the silencing of exogenous transgenes. This mechanism was also operational in cells chronically infected with HIV-1, the etiological agent of AIDS, in a latency state. Indeed, both amino acid starvation and pharmacological inhibition of HDAC4 promoted reactivation of HIV-1 transcription and reverse transcriptase activity production in HDAC4+ ACH-2 T-lymphocytic cells but not in HDAC4− U1 promonocytic cells. Thus, amino acid deprivation leads to transcriptional derepression of silenced transgenes, including integrated plasmids and retroviruses, by a process involving inactivation or down-regulation of HDAC4. These findings suggest that selective targeting of HDAC4 might represent a unique strategy for modulating the expression of therapeutic viral vectors, as well as that of integrated HIV-1 proviruses in latent reservoirs without significant cytotoxicity.

[1]  S. Deeks HIV: Shock and kill , 2012, Nature.

[2]  M. Giacca,et al.  Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex. , 2011, Journal of molecular biology.

[3]  S. Lewin,et al.  HIV cure and eradication: how will we get from the laboratory to effective clinical trials? , 2011, AIDS.

[4]  B. Aronow,et al.  Modulation of chromatin position and gene expression by HDAC4 interaction with nucleoporins , 2011, The Journal of cell biology.

[5]  K. Benabdellah,et al.  Physiological and tissue-specific vectors for treatment of inherited diseases , 2011, Gene Therapy.

[6]  E. Verdin,et al.  Epigenetic regulation of HIV latency , 2011, Current opinion in HIV and AIDS.

[7]  D. Margolis,et al.  Histone deacetylase inhibitors and HIV latency , 2011, Current opinion in HIV and AIDS.

[8]  S. Zeichner,et al.  Cell line-dependent variability in HIV activation employing DNMT inhibitors , 2010, Virology Journal.

[9]  H. Virgin,et al.  Histone Deacetylases and the Nuclear Receptor Corepressor Regulate Lytic-Latent Switch Gene 50 in Murine Gammaherpesvirus 68-Infected Macrophages , 2010, Journal of Virology.

[10]  Su-Ju Lin,et al.  Regulation of yeast sirtuins by NAD(+) metabolism and calorie restriction. , 2010, Biochimica et biophysica acta.

[11]  C. Van Lint,et al.  HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals , 2010, Science.

[12]  A. Mai,et al.  Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. , 2010, Pharmacological research.

[13]  D. Reinberg,et al.  Chromatin structure and the inheritance of epigenetic information , 2010, Nature Reviews Genetics.

[14]  Sung Soon Kim,et al.  Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1 , 2010, AIDS.

[15]  A. Mai,et al.  Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. , 2009, Current pharmaceutical design.

[16]  D. Sabatini,et al.  mTOR signaling at a glance , 2009, Journal of Cell Science.

[17]  Arsène Burny,et al.  Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection , 2009, PloS one.

[18]  H. Prince,et al.  Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.

[19]  D. Hazuda,et al.  The Challenge of Finding a Cure for HIV Infection , 2009, Science.

[20]  Amy S. Espeseth,et al.  Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. , 2009, AIDS research and human retroviruses.

[21]  V. Castronovo,et al.  HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism , 2009, Oncogene.

[22]  A. Kozikowski,et al.  Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. , 2008, Journal of medicinal chemistry.

[23]  A. Ballabio,et al.  The ocular albinism type 1 protein, an intracellular G protein-coupled receptor, regulates melanosome transport in pigment cells , 2008, Human molecular genetics.

[24]  C. Decatur,et al.  L-DOPA Is an Endogenous Ligand for OA1 , 2008, PLoS biology.

[25]  T. Ghosh,et al.  Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development , 2008, Cancer and Metastasis Reviews.

[26]  Guoping Feng,et al.  The Histone Deacetylase HDAC4 Connects Neural Activity to Muscle Transcriptional Reprogramming* , 2007, Journal of Biological Chemistry.

[27]  Liang Da,et al.  CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding , 2007, Nucleic acids research.

[28]  U. Koch,et al.  Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases , 2007, Proceedings of the National Academy of Sciences.

[29]  F. Dequiedt,et al.  Recruitment of chromatin‐modifying enzymes by CTIP2 promotes HIV‐1 transcriptional silencing , 2007, The EMBO journal.

[30]  Richard A Young,et al.  Chromatin immunoprecipitation and microarray-based analysis of protein location , 2006, Nature Protocols.

[31]  Satoshi Inoue,et al.  Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2006, Cancer research.

[32]  R. Piccirillo,et al.  An unconventional dileucine-based motif and a novel cytosolic motif are required for the lysosomal and melanosomal targeting of OA1 , 2006, Journal of Cell Science.

[33]  Cheryl Jennings,et al.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study , 2005, The Lancet.

[34]  Hong Chen,et al.  Nutritional control of gene expression: how mammalian cells respond to amino acid limitation. , 2005, Annual review of nutrition.

[35]  L. Altucci,et al.  Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. , 2005, Journal of medicinal chemistry.

[36]  John M. Shelton,et al.  Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis , 2004, Cell.

[37]  C. Van Lint,et al.  Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. , 2004, Biochemical pharmacology.

[38]  M. Giacca,et al.  Regulation of HIV‐1 gene expression by histone acetylation and factor recruitment at the LTR promoter , 2003, The EMBO journal.

[39]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[40]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[41]  E. Vicenzi,et al.  Envelope-Dependent Restriction of Human Immunodeficiency Virus Type 1 Spreading in CD4+ T Lymphocytes: R5 but Not X4 Viruses Replicate in the Absence of T-Cell Receptor Restimulation , 1999, Journal of Virology.

[42]  A. Ballabio,et al.  Ocular albinism: evidence for a defect in an intracellular signal transduction system , 1999, Nature Genetics.

[43]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[44]  A. Ballabio,et al.  The ocular albinism type 1 gene product is a membrane glycoprotein localized to melanosomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[46]  A. Fauci,et al.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. , 1989, Science.

[47]  A. Fauci,et al.  Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. , 1989, Journal of immunology.

[48]  J. Justement,et al.  Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. , 1988, Journal of immunology.

[49]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[50]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[51]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[52]  L. Altucci,et al.  "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. , 2009, Retrovirology.

[53]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.